106 related articles for article (PubMed ID: 12112981)
21. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
22. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
[TBL] [Abstract][Full Text] [Related]
23. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
24. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
25. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
26. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
27. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
28. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
29. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D
Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741
[TBL] [Abstract][Full Text] [Related]
31. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
Kets CM; Niermeijer MF; Massuger LF; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1709-11. PubMed ID: 15468897
[TBL] [Abstract][Full Text] [Related]
32. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
[TBL] [Abstract][Full Text] [Related]
33. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
34. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
35. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
36. Familial ovarian cancer.
Elit L
Can Fam Physician; 2001 Apr; 47():778-84. PubMed ID: 11340759
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.
Søgaard M; Kjaer SK; Gayther S
Acta Obstet Gynecol Scand; 2006; 85(1):93-105. PubMed ID: 16521688
[TBL] [Abstract][Full Text] [Related]
38. Ovarian cancer, oral contraceptives, and BRCA mutations.
Friedenson B
N Engl J Med; 2001 Dec; 345(23):1707. PubMed ID: 11759653
[No Abstract] [Full Text] [Related]
39. Ovarian cancer, oral contraceptives, and BRCA mutations.
Narod SA; Sun P; Risch HA;
N Engl J Med; 2001 Dec; 345(23):1706-7. PubMed ID: 11759652
[No Abstract] [Full Text] [Related]
40. [Epidemiology and genetics of cancers of the ovary].
Vidal V; Bignon YJ
Rev Prat; 1997 Jun; 47(11):1182-6. PubMed ID: 9238812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
